



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2021 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 981 363 019
Organisasjonsform: Aksjeselskap
Foretaksnavn: ABBOTT DIAGNOSTICS TECHNOLOGIES AS
Forretningsadresse: Kjelsåsveien 161
0884 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2021 - 31.12.2021

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Oddvar Vanberg
Dato for fastsettelse av årsregnskapet: 30.06.2022

Grunnlag for avgivelse

År 2021: Årsregnskapet er elektronisk innlevert
År 2020: Tall er hentet fra elektronisk innlevert årsregnskap fra 2021

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 23.07.2023



Resultatregnskap

| Beløp i: NOK | Note | 2021 | 2020 |
|--|-------|----------------------|--------------------|
| RESULTATREGNSKAP | | | |
| Inntekter | | | |
| Salgsinntekt | 1 | 1 134 062 508 | 876 742 574 |
| Annen driftsinntekt | 2 | 96 810 | 104 980 |
| Sum inntekter | | 1 134 159 318 | 876 847 554 |
| Kostnader | | | |
| Varekostnad | | 325 125 939 | 308 417 605 |
| Lønnskostnad | 3,4 | 140 036 918 | 159 251 684 |
| Avskrivning | 5,6,7 | 31 810 714 | 28 596 895 |
| Annen driftskostnad | 3,6 | 328 905 194 | 216 458 381 |
| Sum kostnader | | 825 878 765 | 712 724 565 |
| Driftsresultat | | 308 280 553 | 164 122 989 |
| Finansinntekter og finanskostnader | | | |
| Renteinntekt fra foretak i samme konsern | | 3 859 746 | 2 211 939 |
| Annen renteinntekt | | 137 | 7 835 |
| Annen finansinntekt | 8 | 42 123 861 | 85 269 315 |
| Sum finansinntekter | | 45 983 744 | 87 489 089 |
| Rentekostnad til foretak i samme konsern | | 129 003 | 90 189 |
| Annen rentekostnad | | 75 907 | 739 394 |
| Annen finanskostnad | 9 | 40 792 306 | 81 314 372 |
| Sum finanskostnader | | 40 997 216 | 82 143 955 |
| Netto finans | | 4 986 528 | 5 345 134 |
| Ordinært resultat før skattekostnad | | 313 267 081 | 169 468 123 |
| Skattekostnad på ordinært resultat | 11 | 887 127 402 | 37 257 796 |
| Ordinært resultat etter skattekostnad | | -573 860 321 | 132 210 327 |
| Ekstraordinære poster | 10 | 3 916 349 810 | |
| Årsresultat | | 3 342 489 489 | 132 210 327 |
| Overføringer og disponeringer | | | |



Resultatregnskap

| Beløp i: NOK | Note | 2021 | 2020 |
|--|-------------|-----------------------|---------------------|
| Ordinært utbytte | | -3 850 000 000 | -229 722 381 |
| Overføring til/fra annen egenkapital | 12 | 507 510 512 | 97 512 054 |
| Sum overføringer og disponeringer | | -3 342 489 488 | -132 210 327 |



Balanse

| Beløp i: NOK | Note | 2021 | 2020 |
|--|-------|----------------------|----------------------|
| BALANSE - EIENDELER | | | |
| Anleggsmidler | | | |
| Immaterielle eiendeler | | | |
| Utsatt skattefordel | 11 | | 23 175 575 |
| Sum immaterielle eiendeler | | 0 | 23 175 575 |
| Varige driftsmidler | | | |
| Maskiner og anlegg | 5 | 177 269 338 | 188 684 487 |
| Skip, rigger, fly og lignende | 5 | 1 172 689 | 863 962 |
| Sum varige driftsmidler | | 178 442 027 | 189 548 449 |
| Finansielle anleggsmidler | | | |
| Investering i datterselskap | | | 34 237 131 |
| Lån til foretak i samme konsern | 13 | 4 063 549 034 | 842 503 715 |
| Sum finansielle anleggsmidler | | 4 063 549 034 | 876 740 846 |
| Sum anleggsmidler | | 4 241 991 061 | 1 089 464 870 |
| Omløpsmidler | | | |
| Varer | | | |
| Varer | 14 | 112 153 763 | 110 325 971 |
| Sum varer | | 112 153 763 | 110 325 971 |
| Fordringer | | | |
| Kundefordringer | 13 | 4 376 829 | 4 755 312 |
| Andre fordringer | 13 | 426 579 352 | 30 932 805 |
| Konsernfordringer | 13,15 | 201 423 155 | 105 407 389 |
| Sum fordringer | | 632 379 336 | 141 095 506 |
| Bankinnskudd, kontanter og lignende | | | |
| Bankinnskudd, kontanter og lignende | 15 | 7 166 485 | 8 455 525 |
| Sum bankinnskudd, kontanter og lignende | | 7 166 485 | 8 455 525 |
| Sum omløpsmidler | | 751 699 584 | 259 877 002 |
| SUM EIENDELER | | 4 993 690 645 | 1 349 341 872 |



Balanse

| Beløp i: NOK | Note | 2021 | 2020 |
|--|------|----------------------|--------------------|
| BALANSE - EGENKAPITAL OG GJELD | | | |
| Egenkapital | | | |
| Innskutt egenkapital | | | |
| Aksjekapital | 12 | 1 000 000 | 1 000 000 |
| Beholdning av egne aksjer | 12 | 41 095 088 | 41 095 088 |
| Sum innskutt egenkapital | | 42 095 088 | 42 095 088 |
| Opptjent egenkapital | | | |
| Annen egenkapital | | 406 989 901 | 914 500 412 |
| Sum opptjent egenkapital | | 406 989 901 | 914 500 412 |
| Sum egenkapital | | 449 084 989 | 956 595 500 |
| Gjeld | | | |
| Langsiktig gjeld | | | |
| Utsatt skatt | 11 | 397 017 821 | |
| Sum avsetninger for forpliktelser | | 397 017 821 | |
| Annen langsiktig gjeld | | | |
| Langsiktig konserngjeld | 13 | 477 | 26 984 |
| Øvrig langsiktig gjeld | | | 92 834 |
| Sum annen langsiktig gjeld | | 477 | 119 818 |
| Sum langsiktig gjeld | | 397 018 298 | 119 818 |
| Kortsiktig gjeld | | | |
| Leverandørgjeld | 13 | 172 181 485 | 75 962 474 |
| Betalbar skatt | 11 | | 41 551 408 |
| Skyldige offentlige avgifter | | 13 524 242 | 15 281 223 |
| Utbytte | | 3 850 000 000 | 229 722 381 |
| Kortsiktig konserngjeld | | | 6 353 422 |
| Annen kortsiktig gjeld | 13 | 111 881 631 | 23 755 646 |
| Sum kortsiktig gjeld | | 4 147 587 358 | 392 626 554 |
| Sum gjeld | | 4 544 605 656 | 392 746 372 |



Balanse

| Beløp i: NOK | Note | 2021 | 2020 |
|---------------------------------|-------------|----------------------|----------------------|
| SUM EGENKAPITAL OG GJELD | | 4 993 690 645 | 1 349 341 872 |



Brønnøysundregistrene

ÅRSREGNSKAP FOR REGNSKAPSÅRET 2021 - GENERELL INFORMASJON

Journalnummer: 2022 874269

Enheten

Organisasjonsnummer: 981 363 019
Organisasjonsform: Aksjeselskap
Foretaksnavn: ABBOTT DIAGNOSTICS TECHNOLOGIES AS
Forretningsadresse: Kjelsåsveien 161
0884 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2021 - 31.12.2021

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av
årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Oddvar Vanberg
Dato for fastsettelse av årsregnskapet: 30.06.2022

Grunnlag for avgivelse

År 2021: Årsregnskap er elektronisk innlevert.
År 2020: Tall er hentet fra elektronisk innlevert årsregnskap fra 2021.

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 16.08.2022



Organisasjonsnr: 981 363 019
ABBOTT DIAGNOSTICS TECHNOLOGIES AS

RESULTATREGNSKAP

| Beløp i: NOK | Note | 2021 | 2020 |
|--|---------|-----------------------|---------------------|
| RESULTATREGNSKAP | | | |
| Inntekter | | | |
| Salgsinntekt | 1 | 1 134 062 508 | 876 742 574 |
| Annen driftsinntekt | 2 | 96 810 | 104 980 |
| Sum inntekter | | 1 134 159 318 | 876 847 554 |
| Kostnader | | | |
| Varekostnad | | 325 125 939 | 308 417 605 |
| Lønnskostnad | 3, 4 | 140 036 918 | 159 251 684 |
| Avskrivning | 5, 6, 7 | 31 810 714 | 28 596 895 |
| Annen driftskostnad | 3, 6 | 328 905 194 | 216 458 381 |
| Sum kostnader | | 825 878 765 | 712 724 565 |
| Driftsresultat | | 308 280 553 | 164 122 989 |
| Finansinntekter og finanskostnader | | | |
| Renteinntekt fra foretak i samme konsern | | 3 859 746 | 2 211 939 |
| Annen renteinntekt | | 137 | 7 835 |
| Annen finansinntekt | 8 | 42 123 861 | 85 269 315 |
| Sum finansinntekter | | 45 983 744 | 87 489 089 |
| Rentekostnad til foretak i samme konsern | | 129 003 | 90 189 |
| Annen rentekostnad | | 75 907 | 739 394 |
| Annen finanskostnad | 9 | 40 792 306 | 81 314 372 |
| Sum finanskostnader | | 40 997 216 | 82 143 955 |
| Netto finans | | 4 986 528 | 5 345 134 |
| Ordinært resultat før skattekostnad | | | |
| Skattekostnad på ordinært resultat | 11 | 887 127 402 | 37 257 796 |
| Ordinært resultat etter skattekostnad | | -573 860 321 | 132 210 327 |
| Ekstraordinære poster | 10 | 3 916 349 810 | |
| Årsresultat | | 3 342 489 489 | 132 210 327 |
| Overføringer og disponeringer | | | |
| Ordinært utbytte | | -3 850 000 000 | -229 722 381 |
| Overføring til/fra annen egenkapital | 12 | 507 510 512 | 97 512 054 |
| Sum overføringer og disponeringer | | -3 342 489 488 | -132 210 327 |



Organisasjonsnr: 981 363 019
ABBOTT DIAGNOSTICS TECHNOLOGIES AS

BALANSE

Beløp i: NOK Note 2021 2020

BALANSE - EIENDELER

Anleggsmidler

Immaterielle eiendeler

Utsatt skattefordel 11 23 175 575
Sum immaterielle eiendeler 0 23 175 575

Varige driftsmidler

Maskiner og anlegg 5 177 269 338 188 684 487
Skip, rigger, fly og lignende 5 1 172 689 863 962
Sum varige driftsmidler 178 442 027 189 548 449

Finansielle anleggsmidler

Investering i datterselskap 34 237 131
Lån til foretak i samme konsern 13 4 063 549 034 842 503 715
Sum finansielle anleggsmidler 4 063 549 034 876 740 846

Sum anleggsmidler 4 241 991 061 1 089 464 870

Omløpsmidler

Varer

Varer 14 112 153 763 110 325 971
Sum varer 112 153 763 110 325 971

Fordringer

Kundefordringer 13 4 376 829 4 755 312
Andre fordringer 13 426 579 352 30 932 805
Konsernfordringer 13, 15 201 423 155 105 407 389
Sum fordringer 632 379 336 141 095 506

Bankinnskudd, kontanter og lignende

Bankinnskudd, kontanter og lignende 15 7 166 485 8 455 525
Sum bankinnskudd, kontanter og lignende 7 166 485 8 455 525

Sum omløpsmidler 751 699 584 259 877 002

SUM EIENDELER 4 993 690 645 1 349 341 872

BALANSE - EGENKAPITAL OG GJELD

Egenkapital

Innskutt egenkapital



| | | | |
|--|----|----------------------|----------------------|
| Aksjekapital | 12 | 1 000 000 | 1 000 000 |
| Beholdning av egne aksjer | 12 | 41 095 088 | 41 095 088 |
| Sum innskutt egenkapital | | 42 095 088 | 42 095 088 |
| Opptjent egenkapital | | | |
| Annen egenkapital | | 406 989 901 | 914 500 412 |
| Sum opptjent egenkapital | | 406 989 901 | 914 500 412 |
| Sum egenkapital | | 449 084 989 | 956 595 500 |
| Gjeld | | | |
| Langsiktig gjeld | | | |
| Utsatt skatt | 11 | 397 017 821 | |
| Sum avsetninger for forpliktelseser | | 397 017 821 | |
| Annen langsiktig gjeld | | | |
| Langsiktig konserngjeld | 13 | 477 | 26 984 |
| Øvrig langsiktig gjeld | | | 92 834 |
| Sum annen langsiktig gjeld | | 477 | 119 818 |
| Sum langsiktig gjeld | | 397 018 298 | 119 818 |
| Kortsiktig gjeld | | | |
| Leverandørgjeld | 13 | 172 181 485 | 75 962 474 |
| Betalbar skatt | 11 | | 41 551 408 |
| Skyldige offentlige avgifter | | 13 524 242 | 15 281 223 |
| Utbytte | | 3 850 000 000 | 229 722 381 |
| Kortsiktig konserngjeld | | | 6 353 422 |
| Annen kortsiktig gjeld | 13 | 111 881 631 | 23 755 646 |
| Sum kortsiktig gjeld | | 4 147 587 358 | 392 626 554 |
| Sum gjeld | | 4 544 605 656 | 392 746 372 |
| SUM EGENKAPITAL OG GJELD | | 4 993 690 645 | 1 349 341 872 |



Organisasjonsnr: 981 363 019
ABBOTT DIAGNOSTICS TECHNOLOGIES AS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note
1

Regnskapsprinsipper

The annual accounts have been prepared in compliance with the Account Act and accounting principles generally accepted in Norway. It coincide to Norwegian accounting standards. Upon application, the company has been granted an exemption from the consolidated accounting obligation for parent companies in subgroups.

Note
16

Antall aksjer og aksjeeiere

| <u>Aksjeklasse</u> | <u>Ant. aksjer</u> | <u>Pålydende</u> | <u>Bokført verdi</u> |
|------------------------------|--------------------|----------------------|----------------------|
| Ordinære aksjer | 1000.00 | 1000.00 | 1000000.00 |
| <u>Aksjeeiere - fritekst</u> | <u>Antall</u> | <u>Eierandel</u> | <u>Aksjeklasse</u> |
| Axis-Shield AS | 1000.00 | 0.00% | |
| <u>Sum</u> | <u>Sum antall</u> | <u>Sum eierandel</u> | |
| | 1000.00 | | |

Abbott Laboratories Inc prepares consolidated financial statements where Abbott Diagnostics Technologies As is included. Consolidated financial statements can be provided by Abbott Laboratories with the address: Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064-3500 USA

Note
3

Lønn og ytelser

| <u>Lønn</u> | <u>Årets</u> | <u>Fjorårets</u> |
|---------------------------|--------------|------------------|
| | 156284000.00 | 167667000.00 |
| <u>Arbeidsgiveravgift</u> | <u>Årets</u> | <u>Fjorårets</u> |
| | 25246000.00 | 24180000.00 |
| <u>Pensjonskostnader</u> | <u>Årets</u> | <u>Fjorårets</u> |
| | 10844000.00 | 12067000.00 |
| <u>Andre ytelser</u> | <u>Årets</u> | <u>Fjorårets</u> |
| | 7107000.00 | 7550000.00 |
| <u>Sum lønnskostnader</u> | <u>Årets</u> | <u>Fjorårets</u> |



199481000.00 211464000.00

Included in cost of goods 2021: - 59 445 000. Total = 140 037 000
2020: - 52 211 000. Total = 159 252 000

Note

3

Ytelser til ledende personer

Ytelser til daglig leder

| <u>Ytelser</u> | <u>Lønn</u> | <u>Pensj.forpl.</u> | <u>Andre godtgj.</u> |
|----------------|-------------|---------------------|----------------------|
| | 2421000.00 | | |

There is no special remuneration agreed for the CEO or the board in case of resignation or change in employment. No special remuneration such as bonuses and provisions agreed.

Note

3

Ytelser til revisjon

Fees of statutory audit in 2021 have been expensed with NOK 439 804 excl. VAT.

Note

3

Antall årsverk i regnskapsåret

Virksomheten har hatt følgende antall årsverk:
288.00

Note

Lån og sikkerhetsstillelse til ledende personer og aksjeeiere

Er det gitt lån eller sikkerhetsstillelse til ledende personer: Nei

Omløpsmidler Startdato Sluttdato Endring

Skattemessig fremf.undersk. Startdato Sluttdato Endring

Kortsiktig gjeld Startdato Sluttdato Endring



Statsautoriserte revisorer
Ernst & Young AS

Dronning Eufemias gate 6a, 0191 Oslo
Postboks 1156 Sentrum, 0107 Oslo

Foretaksregisteret: NO 976 389 387 MVA
Tlf: +47 24 00 24 00

www.ey.no
Medlemmer av Den norske Revisorforening

INDEPENDENT AUDITOR'S REPORT

To the Annual Shareholders' Meeting of Abbott Diagnostics Technologies AS

Opinion

We have audited the financial statements of Abbott Diagnostics Technologies AS (the Company), which comprise balance sheet as at 31 December 2021, the income statement and cash flow statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion the financial statements comply with applicable legal requirements and give a true and fair view of the financial position of the Company as at 31 December 2021 and its financial performance and cash flows for the year then ended in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Company in accordance with the requirements of the relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' *International Code of Ethics for Professional Accountants (including International Independence Standards)* (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

Other information consists of the information included in the annual report other than the financial statements and our auditor's report thereon. Management (the board of directors and Chief Executive Officer) is responsible for the other information. Our opinion on the financial statements does not cover the other information, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information, and, in doing so, consider whether the board of directors' report contains the information required by legal requirements and whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information or that the information required by legal requirements is not included, we are required to report that fact.

We have nothing to report in this regard, and in our opinion, the board of directors' report is consistent with the financial statements and contains the information required by applicable legal requirements.

Responsibilities of management for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the



Building a better
working world

going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Oslo, 8 July 2022
ERNST & YOUNG AS

The auditor's report is signed electronically

Kjetil Andersen
State Authorised Public Accountant (Norway)

Independent auditor's report - Abbott Diagnostics Technologies AS 2021

A member firm of Ernst & Young Global Limited

Penneo Dokumentnøkkel: MM15S-VC6SP-5VLW7-24XUU-UJOG4-E01ZJ



PENNEO

Signaturene i dette dokumentet er juridisk bindende. Dokument signert med "Penneo™ - sikker digital signatur".
De signerende parter sin identitet er registrert, og er listet nedenfor.

"Med min signatur bekrefter jeg alle datoer og innholdet i dette dokument."

Kjetil Andersen

Statsautorisert revisor

På vegne av: ERNST & YOUNG AS

Serienummer: 9578-5992-4-2398085

IP: 213.52.xxx.xxx

2022-07-08 15:42:28 UTC



Penneo DokumentInokkelt: MM15S-VCGSP-5VILW7-24XJU-UJOG4-E01ZJ

Dokumentet er signert digitalt, med **Penneo.com**. Alle digitale signatur-data i dokumentet er sikret og validert av den datamaskin-utregnede hash-verdien av det opprinnelige dokument. Dokumentet er låst og tids-stemplet med et sertifikat fra en betrodd tredjepart. All kryptografisk bevis er integrert i denne PDF, for fremtidig validering (hvis nødvendig).

Hvordan bekrefter at dette dokumentet er originalen?

Dokumentet er beskyttet av ett Adobe CDS sertifikat. Når du åpner dokumentet i

Adobe Reader, skal du kunne se at dokumentet er sertifisert av **Penneo e-signature service <penneo@penneo.com>**. Dette garanterer at innholdet i dokumentet ikke har blitt endret.

Det er lett å kontrollere de kryptografiske beviser som er lokalisert inne i dokumentet, med Penneo validator - <https://penneo.com/validate>



Skatteetaten

Vår dato
18.07.2022

Din/Deres dato

Saksbehandler
Robin Ingebrigtsen

800 80 000
Skatteetaten.no

Din/Deres referanse

Telefon
99778267

Org.nr
974761076

Vår referanse
2022/5641181

Postadresse
Postboks 9200 Grønland
0134 OSLO

ABBOTT DIAGNOSTICS TECHNOLOGIES AS
Postboks 6863 Rodeløkka
0504 OSLO

Dispensasjon fra kravet om å utarbeide årsregnskap og årsberetning på norsk

Vi viser til Abbott Diagnostics Technologies AS (org.nr. 981 363 019) sin søknad om dispensasjon fra kravet om å utarbeide årsregnskap og årsberetning på norsk.

Skattekontoret gir på bakgrunn av en konkret helhetsvurdering selskapet dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen forutsetter at engelsk språk benyttes i stedet ved utarbeidelsen, og at øvrige opplysninger som vedtaket baserer seg på, heller ikke endres vesentlig.

Kopi av dette brevet må sendes Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Det påligger den regnskapspliktige å dokumentere ved dette brev at tillatelsen er gitt.

Bakgrunn

Fra søknaden siteres:

Abbott Diagnostics Technologies AS sender herved søknad om å levere årsregnskap og årsberetning på engelsk.

Abbott Diagnostics Technologies AS er et selskap i Abbott Laboratories konsernet og er 100 % eid av Axis Shield AS, som igjen eies 100% av Axis Shield Ltd, som har forretningsadresse i Storbritannia.

Dette er et internasjonalt konsern, hvor den ultimate eier er Abbott Laboratories Inc som er børsnotert og har forretningsadresse i USA.

Abbott Diagnostics Technologies AS sin virksomhet består av å levere produkter og tjenester til helsesektoren internasjonalt. Selskapet er en del av et internasjonalt konsern der finansiell informasjon rapporteres gjennom flere selskapsledd. Dette gjør at kommunikasjon, inkludert finansiell informasjon, for det alt vesentlige skjer på engelsk.

Administrerende direktør er amerikansk statsborger og er dessuten et av to styremedlemmer i



selskapet. Det er derfor et stort behov for at årsregnskap og årsberetning presenteres på engelsk. Det bes på denne bakgrunn om fritak fra å levere årsregnskap og årsberetning på norsk og at årsregnskap og årsberetning kan leveres på engelsk.

Skattekontorets vurdering

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen ... være på norsk. Departementet kan ved ... enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap mv., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon.

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i proposisjonen, blant andre investorer, kreditorer, ansatte, kunder og lokalsamfunnet.

Det er etter skattekontorets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Som nevnt ovenfor er det særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I dette tilfellet er det opplyst at kommunikasjon med de fleste av kunder og leverandører skjer på engelsk. Selskapets eiere er engelskspråklige og vil ikke ha mulighet for å forstå årsregnskap og årsberetning på norsk. Skattekontoret finner at disse forholdene samlet tilsier at dispensasjon fra kravet om å utarbeide årsregnskap og årsberetning på norsk kan gis.

Vennligst oppgi vår referanse ved henvendelse i saken.



Med hilsen

Magrit Kilen Støebner
underdirektør
Innsats, storbedrift
Skatteetaten

Robin Ingebrigtsen

Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer.



**Annual accounts 2021
for
Abbott Diagnostics Technologies AS**



Abbott Diagnostics Technologies AS

Annual Report 2021

OVERVIEW OF THE BUSINESS

The company conducts research and development, production and distribution of in vitro diagnostic products. The company's products are sold to doctors' offices and hospital laboratories in more than 100 countries. In 2021, sales outside Norway were 88% of total. United States, Europe, China, Mexico, India, South Korea, Indonesia and Japan were the most important export markets.

Operating revenues increased by 29.3% compared to 2020. Afinion test sales increased by 31% in volume, and the volume for NycoCard tests was reduced by 5%.

Tests available on the Afinion instrument include CRP, HbA1c, ACR and Lipid panel.

Three (3) fully automated production lines for the Afinion tests are in operation, and a fourth has been installed and qualified. The company is continuously working to improve quality, cost and efficiency.

The NycoCard™ platform still appears to be a good quantitative diagnostic analysis system primarily used in smaller laboratories. The platform is mainly used in Asia and Latin America. Tests available on the NycoCard™ instrument in 2021 were CRP and HbA1c.

RESEARCH AND DEVELOPMENT

The company's research department conducts specific research and development projects with the goal of developing instrumentation and new in-vitro diagnostic analysis products for the global Point-of-Care market. The research department also supports the group's other companies with research projects in the early stages.

The following main R&D activities were the focus of 2021:

- Development of a second generation analysis product for measuring lipids on Afinion ("Afinion Lipid Panel") against "CLIA-waiver" status in the USA
- Launch of second-generation, CE-marked, analysis product for measuring HbA1c on the company's world-leading analysis platform Afinion; «Afinion HbA1c dx».
- Clinical trials in the US to achieve CLIA waiver status on «Afinion HbA1c dx»
- Exploratory activities for the development of a future second-generation "Clia waived" assay product for measuring ACR (albumin-creatinine ratio) on Afinion (which, together with HbA1c, is essential in the follow-up of patients with diabetes).

CONTINUING OPERATION

In accordance with the Accounting Act §3-3a, it is confirmed that the preconditions for continued operations are present. The assumption is based on profit forecasts for 2022 and as well the company's long-term strategic forecasts for the years ahead. The company is in a sound financial position.

The year 2021 continued to be essentially characterized by COVID 19, declared as a pandemic by the World Health Organization on March 11, 2020. The company has implemented appropriate measures for its employees, who have continued to work without interruption of company activities. The company remained profitable in 2021 and will monitor all activities of the pandemic and introduce all



Abbott Diagnostics Technologies AS

Annual Report 2021

measures necessary to continue to deliver a profitable performance in 2022.

HEALTH – ENVIRONMENTAL - SAFETY

In 2021, the company has ensured systematic HSE work at all levels in accordance with Norwegian law and Abbott Group requirements. Common HSE policy, goals and guidelines have been established. The HSE activities are an integrated part of the company's operating system, as well as daily work in production, project, and product. Activities for 2021 were carried out as planned.

Sickness absence for 2021 was 6.9%, an increase from 2020 when sickness absence was 6.1%.

The company collaborates with internal and external occupational health services to carry out preventive work, and to prevent or reduce stress and other illness. The company implements continuous measures to assess performance and take corrective actions when necessary.

There have been zero work-related injuries with absence registered in 2021.

Pollution to the external environment is monitored has been reduced through relevant action plans.

The company has contingency plans and an industrial protection organization.

EQUALITY

The company's goal is to be a workplace where there is fully equality between women and men. It is desirable to have a balance between women and men in all functions and departments in Abbott Diagnostics Technologies AS. Out of company's 288 employees, 146 were women and 142 men.

The company's management has good representation of both sexes, 4 women and 2 men.

The company has a good balance within all age groups that take care of a balanced work environment and competence distribution.

NFI REPORTING

For 2021, Abbott has achieved a representative gender balance of employees. Approximately 50% were women and 50% were men.

Representation across job categories includes: 1 female and 1 male Directors; 6 female and 6 male Managers, 9 female and 4 male Senior Specialists, 60 female and 53 male Specialists, 30 female and 47 male Operator/Associates, and 1 Intern. Three (3) women and two (2) men took parental leave with women averaging 11 weeks and men averaging 3 weeks of leave, and 5 women and 2 men participated in voluntary part-time employment. There were 12 temporary Senior Specialists (7 female and 5 male).

Pay is not determined based on gender and is generally based on the skills, experience, and the job complexity of each position.

Pay differences were assessed for job categories with the following findings: for Managers, the average female pay was 112% of the average pay for Managers and average male pay was 88%; for



Abbott Diagnostics Technologies AS

Annual Report 2021

Senior Specialists, the average female pay was 98% of the average pay for Senior Specialists and average male pay was 103%; for Specialist, the average female pay was 96% of the average pay for Specialists and the average male pay was 104%; for Operator/Associates, the average female pay was 95% of the average pay for Operator/Associates, and average male pay was 103%; and there were less than five Directors and Interns.

Abbott deploys no different policies for sub-groups, and no risk of discrimination were identified during the assessment. To continue this state, we will keep reinforcing our focus on avoiding discrimination, of all kind, in our policies, programs, and practices to make sure we deliver on our commitments to our employees and to the communities where they live and work.

INSURANCE COVERAGE

The board of directors and general manager are indemnified by the company for the responsibilities they perform on the company behalf up to a limit of US\$10 million via Directors & Officers Liability insurance policy held with Zurich UK Insurances.

FUTURE DEVELOPMENT

The company still sees exciting growth opportunities with today's products, mainly related to the Afinion platform. Throughout 2021, significant resources have also been invested in projects related to the further development of the Afinion platform.

Afinion 2 continues Abbott's work in diabetes treatment by providing patients with information about their health that they can discuss with their doctor during one and the same doctor's visit. The global increase in diabetes provides increased opportunities for our products, and we offer a panel of tests for follow-up of these patients. Afinion™ HbA1c Dx, the first and only patient-centered test approved for use in the diagnosis of diabetes and prediabetes in the United States, was launched in June 2019. The company continues to work to obtain approval of Afinion HbA1c Dx for use in a doctor's office with a CLIA waived license.

Increased focus on antibiotic resistance means that the company also expects increased demand for Afinion™ CRP.

The USA is an important growth area for Afinion™, but good growth is also seen in countries such as Germany, Japan and Brazil.

Abbott Diagnostics Technologies AS is well prepared for further growth.

FINANCIAL RISK

The company's financial risk is primarily related to currency fluctuations. Of total operating revenues, 88% is in foreign currency.

The group has an active currency hedging policy and makes ongoing assessments of exposure. The company actively seeks to place costs in the same currency as the income.



Abbott Diagnostics Technologies AS

Annual Report 2021

The company's credit risk is considered limited as the company has a customer base that has historically shown a very good ability to pay.

PROFIT, INVESTMENTS, FINANCING AND LIQUIDITY

Turnover increased from NOK 876.7 million in 2020 to NOK 1.134. million in 2021. Profit before tax was NOK 4.230 million, including extraordinary income of NOK 3.916 million.

On August 31st 2021 Abbott Diagnostics Technologies AS sold intellectual property to an Abbott affiliate for NOK 3.721 million.

Profit in 2021 was characterized by higher sale to other Abbott affiliates. Costs increased in line with higher revenues and overall the company continues to show a strong economic performance.

The company's liquidity as of 31.12.2021 was NOK 7.2 million. The company is part of the group's cash pooling account scheme with other Abbott companies in Norway. The company's financial position is good.


The total capital as of 31.12.2021 NOK 4.993,7 million, which is an increase of NOK 3,644.3 as of 31.12.2020. Equity as NOK 449.1 million after allocated dividend of NOK 3,850 million which is a decrease of NOK 507.5 million.


ANNUAL RESULT AND ALLOCATION OF EARNINGS

The board proposes the following allocation of the company's profits:

| | |
|------------------------------------|----------------------|
| Dividends | NOK 3,850,000,000 |
| Transferred from retained earnings | NOK (507,510,512), - |

Oslo, 30. June 2022


Oddvar Vanberg
Chairman


Todd Thessen
CEO/Board Member



ABBOTT DIAGNOSTICS TECHNOLOGIES AS

Org. nr./reg. no. 981 363 019

PROTOKOLL FRA STYREMØTE

**MINUTES OF MEETING OF THE
BOARD OF DIRECTORS**

Styremøte i Abbott Diagnostics Technologies AS ble avholdt 30. juni 2022 i Oslo.

A meeting of the Board of Directors of Abbott Diagnostics Technologies AS was held on 30. June 2022 in Oslo.

Følgende styremedlemmer deltok:

The following directors attended:

- Oddvar Arne Vanberg, styrets leder
- Todd Eric Thessen, styremedlem

- Oddvar Arne Vanberg, chairman
- Todd Eric Thessen, board member

Styret var dermed beslutningsdyktig.

A quorum was constituted.

Styreleder ledet møtet.

The meeting was chaired by the Chairman.

Til behandling forelå følgende saker:

The agenda was as follows:

**1. GODKJENNELSE AV INNKALLING OG
AGENDA**

**1. APPROVAL OF THE NOTICE OF MEETING
AND THE AGENDA**

Innkalling til styremøtet og forslag til dagsorden ble godkjent.

The notice of the meeting and the proposed agenda were approved.

**2. ÅRSREGNSKAP OG ÅRSBERETNING,
HERUNDER UTDELING AV UTBYTTE**

**2. ANNUAL ACCOUNTS AND ANNUAL
REPORT, INCLUDING DISTRIBUTION OF
DIVIDEND**

Det ble fremlagt forslag til årsregnskap og årsberetning, samt utkast til revisors beretning. Styret vedtok enstemmig forslaget til årsregnskap og årsberetning. Utkast til revisors beretning ble tatt til etterretning.

Draft annual accounts and annual report, as well as draft auditor's report were presented. The board unanimously approved the annual accounts and the annual report. The draft auditor's report was noted.

Det foreslås at selskapets overskudd for regnskapsåret 2021 kr 3.342.489.488 skal utbetales som utbytte med NOK 3.850.000.000 og at NOK 507.510.512 overføres fra annen egenkapital.

The board proposed that the company's profit financial year, NOK 3.342.489.488 shall be paid as dividend with NOK 3.850.000.000 and that NOK 507.510.512 is transferred from other equity.

Styret var av den oppfatning at selskapet etter utdelingen har tilstrekkelig egenkapital og

The Board considered that the Company after the distribution had equity and liquidity



likviditet hensett til risiko og omfang av selskapets virksomhet, jf. aksjeloven § 3-4. I tillegg vil selskapet ha tilstrekkelig netto eiendeler som dekker selskapets aksjekapital og annen bundet egenkapital og annen bundet egenkapital, jf. aksjeloven § 8-1.

adequate in terms of the risk and scope of the Company's business, cf. section 3-4 of the NPLLCA. In addition, the Company will have sufficient net assets covering the share capital of the Company and other restricted equity cf. section 8-1 of the NPLLCA.

3. HONORAR TIL STYRET

Styret foreslår at det ikke betales godtgjørelse til styret for utøvelsen av styrevervet for regnskapsåret 2021.

3. REMUNERATION TO THE BOARD

The board proposes that no compensation shall be paid for the chairperson and the other directors' services for the financial year of 2021.

4. HONORAR TIL REVISOR

Styret foreslår at revisors bistand til selskapets revisjon m.v. for regnskapsåret 2021 godtgjøres etter regning.

4. FEES TO THE AUDITOR

The board proposes that the auditor's services for the financial year 2021 is compensated according to the auditor's invoices.

5. INNKALLING TIL GENERALFORSAMLING

Styret besluttet enstemmig å innkalle til ordinær generalforsamling i selskapet for behandling av de angitte saker den 30. Juni 2022.

Styrets leder har fullmakt til å signere innkallingen til generalforsamling.

6. NOTICE OF A GENERAL MEETING

The board unanimously resolved to convene the ordinary general meeting to deliberate the proposed matters. The general meeting shall be held on the 30. June 2022.

The chairperson is authorised to sign the notice of the general meeting.

Det forelå ingen flere saker til behandling. Alle beslutninger var enstemmige. Møtet ble hevet og protokollen signert.

There were no further matters on the agenda. All resolutions were unanimous. The meeting was adjourned, and the minutes were signed.

Oslo, 30. Juni 2022

Styret i Abbott Diagnostics Technologies AS / the board of Abbott Diagnostics Technologies AS

Oddvar Arne Vanberg

Styres leder/chairman

Todd Eric Thessen

Styremedlem/director



Abbott Diagnostics Technologies AS

Income Statement

for the period 1 January to 31 December 2021

| OPERATING INCOME AND OPERATING EXPENSES | Note | 2021 | 2020 |
|--|-------------|----------------------|--------------------|
| Operating income | | | |
| Sales revenue | 1 | 1 134 062 508 | 876 742 574 |
| Other revenue | 2 | 96 810 | 104 980 |
| Total operating income | | 1 134 159 318 | 876 847 554 |
| Operating expenses | | | |
| Cost of goods sold | | 325 125 939 | 308 417 605 |
| Employee benefits expense | 3, 4 | 140 036 918 | 159 251 684 |
| Depreciation | 5, 6, 7 | 31 810 714 | 28 596 895 |
| Operating expenses | 3, 6 | 328 905 194 | 216 458 381 |
| Total operating expenses | | 825 878 765 | 712 724 566 |
| OPERATING PROFIT | | 308 280 552 | 164 122 988 |
| FINANCIAL INCOME AND EXPENSES | | | |
| Financial income | | | |
| Interest income from group companies | | 3 859 746 | 2 211 939 |
| Other interest income | | 137 | 7 835 |
| Other financial income | 8 | 42 123 861 | 85 269 315 |
| Net financial items | | 45 983 744 | 87 489 089 |
| Financial expenses | | | |
| Interest expense to group companies | | 129 003 | 90 189 |
| Other interest expenses | | 75 907 | 739 394 |
| Other financial expenses | 9 | 40 792 306 | 81 314 372 |
| Net financial expenses | | 40 997 216 | 82 143 955 |
| NET FINANCIAL ITEMS | | 4 986 528 | 5 345 134 |
| PROFIT BEFORE EXTRAORDINARY ITEMS | | 313 267 080 | 169 468 122 |
| Extraordinary income | 10 | 3 916 349 810 | 0 |
| Net extraordinary income | | 3 916 349 810 | 0 |
| PROFIT BEFORE TAX | | 4 229 616 890 | 169 468 122 |
| Taxes | 11 | 887 127 402 | 37 257 796 |
| NET PROFIT FOR THE YEAR | | 3 342 489 488 | 132 210 327 |
| TRANSFERS AND ALLOCATIONS | | | |
| Dividends | | 3 850 000 000 | 229 722 381 |
| From equity | 12 | (507 510 512) | (97 512 054) |
| TOTAL | | 3 342 489 488 | 132 210 327 |



Abbott Diagnostics Technologies AS
Balance sheet as at 31. December 2021


| ASSETS | Note | 2021 | 2020 |
|---|--------|----------------------|----------------------|
| Non-current assets | | | |
| Intangible assets | | | |
| Deffered tax benefit | 11 | 0 | 23 175 575 |
| Total intangible assets | | 0 | 23 175 575 |
| Tangible assets | | | |
| Machinery and equipment | 5 | 177 269 338 | 188 684 487 |
| Fixture and furnitures | 5 | 1 172 689 | 863 962 |
| Total fixed assets | | 178 442 028 | 189 548 449 |
| Non-current financial assets | | | |
| Investments in subsidiaries | | 0 | 34 237 131 |
| Loan to group companies | 13 | 4 063 549 034 | 842 503 715 |
| Total non-current financial assets | | 4 063 549 034 | 876 740 846 |
| Total non-current assets | | 4 241 991 062 | 1 089 464 869 |
| Current assets | | | |
| Inventory | 14 | 112 153 763 | 110 325 971 |
| Receivables | | | |
| Accounts receivables | 13 | 4 376 829 | 4 755 312 |
| Accounts receivables intercompany | 13, 15 | 146 818 000 | 105 407 389 |
| Other short-term receivables | 13 | 84 000 055 | 30 932 805 |
| Other intercompany receivables | | 54 605 155 | 0 |
| Advance tax | | 342 579 297 | 0 |
| Total receivables | | 632 379 336 | 141 095 506 |
| Cash and cash equivalents | 15 | 7 166 484 | 8 455 525 |
| Total current assets | | 751 699 582 | 259 877 002 |
| Total assets | | 4 993 690 645 | 1 349 341 872 |



Abbott Diagnostics Technologies AS
Balance sheet as at 31. December 2021

| EQUITY AND LIABILITIES | Note | 2021 | 2020 |
|--------------------------------------|-----------|----------------------|----------------------|
| Equity | | | |
| Paid-in capital | | | |
| Share capital | 12 | 1 000 000 | 1 000 000 |
| Share premium reserve | 12 | 41 095 088 | 41 095 088 |
| Total paid-in capital | | 42 095 088 | 42 095 088 |
| Earned capital | | | |
| Retained earnings | | 406 989 901 | 914 500 412 |
| Total equity | | 406 989 901 | 914 500 412 |
| Total capital | 12 | 449 084 989 | 956 595 500 |
| Liabilities | | | |
| Non-current liabilities | | | |
| Deferred tax liability | 11 | 397 017 821 | 0 |
| Non-current liabilities intercompany | 13 | 477 | 26 984 |
| Other non-current liabilities | | 0 | 92 834 |
| Total provisions | | 397 018 298 | 119 818 |
| Current liabilities | | | |
| Account payables | 13 | 172 181 485 | 75 962 474 |
| Company income tax payable | 11 | 0 | 41 551 408 |
| Public duties payable | | 13 524 242 | 15 281 223 |
| Dividends | | 3 850 000 000 | 229 722 381 |
| Current liabilities intercompany | | 0 | 6 353 422 |
| Other current liabilities | 13 | 111 881 631 | 23 755 646 |
| Total current liabilities | | 4 147 587 358 | 392 626 554 |
| Total liabilities | | 4 544 605 656 | 392 746 372 |
| Total equity and liabilities | | 4 993 690 645 | 1 349 341 872 |

The board of Abbott Diagnostics Technologies AS


Oddvar Arne Vanberg
Chairman of the Board


Todd Eric Thessen
CEO / Board Member



Abbott Diagnostics Technologies AS

Cash flow statement 2021

Figures given in thousand

| | Note | 2021 | 2020 |
|---|------|-----------------|----------------|
| Cash flows from operating activities | | | |
| Profit before tax | | 4 229 617 | 169 468 |
| Taxation paid | | -851 064 | -65 126 |
| Depreciation | | 31 811 | 28 597 |
| Loss on disposal fixed assets | | 93 | 0 |
| Changes inventory, receivables and payables | | 53 358 | 46 788 |
| Change in other current assets/liabilities | | 37 750 | -46 196 |
| Gain sales Intellectual Property | | -3 720 865 | 0 |
| Gain on sales shares in subsidiaries | | -195 485 | 0 |
| Net cash flows from operating activities | | -414 785 | 133 531 |
| Cash flow from investment activities | | | |
| Investments in fixed assets | | -20 797 | -49 086 |
| Changes loan group companies | | -3 221 045 | -21 639 |
| Sales on Intellectual Property | | 3 720 865 | 0 |
| Sales on shares in subsidiaries | | 229 722 | 0 |
| Net cash flows from investment activities | | 708 745 | -70 725 |
| Cash flows from financing activities | | | |
| Dividends paid | | -229 722 | 0 |
| Changes in long-term debt | | -93 | -127 |
| Changes in receivable intercompany | | -27 | -100 593 |
| Changes in cash pool | | -65 407 | 39 071 |
| Net cash flows from financing activities | | -295 249 | -61 649 |
| Net change in cash and cash equivalents | | -1 289 | 1 157 |
| Cash and cash equivalents at the start of the period | | 8 456 | 7 298 |
| Cash and cash equivalents at the end of the period | | 7 166 | 8 455 |



Accounting policies

Basic Policies

The annual accounts have been prepared in compliance with the Accounting Act and accounting principles generally accepted in Norway. It coincide to Norwegian accounting standards.

Upon application, the company has been granted an exemption from the consolidated accounting obligation for parent companies in subgroups.

Consolidated financial statements are prepared by Alere Inc.

Subsidiary / associated company

Subsidiaries are valued according to the cost method in the company accounts. The investment is valued at acquisition cost for the shares unless write-down has been necessary. Impairment has been made at fair value when impairment is due to reasons that cannot be assumed to be temporary, and this must be considered necessary in accordance with generally accepted accounting principles. Impairment losses are reversed when the basis for impairment is no longer present

Revenue recognition

Revenue recognition from the sale of goods takes place at the time of delivery. Royalty in connection with the sale of goods is recognized as income when this has been earned in accordance with reported sales to the end user.

When recognizing income in foreign currency, the exchange rate is used at the time of posting.

Research, development and patent costs

Own research and development costs and costs for registration and maintenance of associated patents are expensed.

Classification and assessment of balance sheet items

Current assets and current liabilities include items that fall due for payment within one year after the balance sheet date, as well as items related to the product cycle. Other items are classified as fixed assets/long-term debt.

Current assets are valued at the lower of acquisition cost and fair value. Current liabilities are capitalized at the nominal amount at the time of establishment.

Fixed assets are valued at acquisition cost, but are written down to fair value if the impairment is not expected to be temporary. Long-term debt is capitalized at the nominal amount at the time of establishment.

Receivables

Accounts receivable and other receivables are entered in the balance sheet at par value after deduction of provisions for expected losses. Accruals for losses are made on the basis of an individual assessment of the individual receivable.

Currency

Monetary items, receivables and liabilities in foreign currency are valued at the exchange rate at the end of the financial year.

The effect of changes is included in the income statement.

Fixed assets

Property, plant and equipment are capitalized and depreciated over the life of the fixed asset if they have a useful life of more than three years and a cost price that exceeds NOK 15,000.

Leasing

A distinction is made between financial and operational leasing after a specific assessment of the individual agreement. By financial leasing is meant agreements where the tenant takes over most of the benefits and risks associated with owning the fixed asset. Existing leasing agreements are considered to be operational, which means that leasing rent is expensed on an ongoing basis.

Intangible assets

Purchased research and development projects, patents, trademarks and goodwill are capitalized. Patents are depreciated over the patent's validity period. Other intangible assets are depreciated over their estimated economic life, provided that the asset can be valued independently.

Bank deposit



The group's liquidity is organized in a group account scheme. This means that the subsidiaries' cash holdings are formally receivables from the parent company, and that all group companies are jointly and severally liable for the moves the group has made.

Tax

The tax expense in the income statement includes both the tax payable for the period and the change in deferred tax. Deferred tax is calculated at 22% on the basis of the temporary differences that exist between accounting and tax values, as well as tax losses carried forward at the end of the financial year. Tax-increasing and tax-reducing temporary differences that reverse or can reverse in the same period are offset and netted. Recognition of deferred tax assets is recognized when it is overwhelmingly probable that tax-reducing temporary differences can be utilized through income in future years.

Cash flow statement

Liquidity is defined as the sum of cash and bank deposits. The cash flow statement has been prepared according to the indirect method.



Figures given in thousands

Note 1 - Sales revenue

| Geografic breakdown | 2021 | 2020 |
|----------------------------|------------------|----------------|
| Europe | 299 831 | 285 602 |
| USA | 580 643 | 465 056 |
| Other countries | 253 588 | 126 085 |
| TOTAL | 1 134 062 | 876 743 |

Note 2 - Other operational income

| | 2021 | 2020 |
|--------------|-------------|-------------|
| Royalties | 97 | 105 |
| TOTAL | 97 | 105 |

Note 3 - Employee benefits

Salary costs

| | 2021 | 2020 |
|----------------------------|----------------|----------------|
| Salaries | 156 284 | 167 667 |
| Employment tax | 25 246 | 24 180 |
| Pension expenses | 7 643 | 8 893 |
| Expenses related to AFP | 3 201 | 3 174 |
| Other remuneration | 7 107 | 7 550 |
| Included in costs of goods | -59 445 | -52 211 |
| TOTAL | 140 037 | 159 252 |

There was 288 employees per 31.12.2021

| Benefits to senior executives | CEO | Board members |
|--------------------------------------|------------|----------------------|
| Salaries | 2 421 | 0 |

There is no special remuneration agreed for the CEO or the board in case of resignation or change in employment. No special remuneration such as bonuses and provisions agreed.

Audit

Fees for statutory audit in 2021 have been expensed with NOK 439 804 excl. VAT.



Figures given in thousands

Note 4 - Pension obligations

Pension costs and pension obligations

The company is obliged to have an occupational pension scheme in accordance with the Act on Mandatory Occupational Pensions, and the pension scheme meets the requirements of this Act.

The company has in 2021 contribution-based pension scheme.

The defined contribution pension comprises 288 employees in 2021. Premium paid for the period 01.01.2021 - 31.12.2021 amounts to NOK 7 643 477.

The company has a contractual early retirement scheme (AFP). The new AFP scheme, which applies from 1 January 2011, is to be regarded as a defined benefit plan, but is accounted for as a defined contribution scheme until reliable and sufficient information is available so that the group can account for its proportionate share of pension costs, pension obligations and pension assets. arrangement. The company's liabilities are thus not capitalized as debt.



Figures given in thousands

Note 5 - Tangible assets

| | Assets under construction | Machines/equipment | Investments rented building | Other | Total |
|-----------------------------------|---------------------------|--------------------|-----------------------------|----------|----------------|
| Cost price 01.01.2021 | 99 984 | 463 096 | 63 943 | 809 | 627 831 |
| Additions | 15 336 | 5 385 | 76 | 0 | 20 797 |
| Disposal | 0 | -760 | -674 | -809 | -2 243 |
| Transfers | -22 207 | 18 727 | 3 480 | 0 | 0 |
| Cost price 31.12.2021 | 93 113 | 486 447 | 66 825 | 0 | 646 385 |
| Accumulated depreciation 01.01 | 0 | 376 713 | 60 760 | 0 | 437 473 |
| Accumulated depreciation 31.12 | 0 | 406 308 | 61 635 | 0 | 467 943 |
| Carrying amount 31.12.2021 | 93 113 | 80 139 | 5 190 | 0 | 178 442 |
| Depreciation for the year | 0 | 30 286 | 1 524 | 0 | 31 811 |

The company uses straight-line depreciation for all intangible assets and property, plant and equipment. The economic life of the fixed assets is calculated at:

| | |
|----------------------------------|------------|
| Investments in rented buildings | 10 years |
| Machines and inventory | 3-10 years |
| Trademarks | 5 years |
| Patents | 12 years |
| Goodwill | 20 years |
| Software/other intangible assets | 10 years |

The discounted excess return for the acquired businesses is expected to exceed the book values at any given time.

Information on leases/operating leases (annual rent)

| | 2021 | 2020 | Remaining duration |
|--------------------|---------------|---------------|--------------------|
| Buildings | 21 958 | 24 930 | 6 years |
| Machines/equipment | 652 | 562 | 1-5 years |
| Total | 22 610 | 25 492 | |



Figures given in thousands

Note 6 - Licences and patents

| | Patents | Trademarks | Software/ other intangible | TOTAL |
|--|----------|------------|----------------------------------|----------|
| Acquisition cost per. 01.01.2021 | 128 000 | 21 137 | 97 746 | 246 883 |
| Disposal of intangible assets | -128 000 | 0 | -97 746 | -225 746 |
| Acquisition cost 31.12.2021 | 0 | 21 137 | 0 | 21 137 |
| Acc .depreciation and write-downs pr. 31.12.2021 | 0 | 21 137 | 0 | 21 137 |
| carrying amount 31.12.2021 | 0 | 0 | 0 | 0 |
| Ordinary depreciation for the year | 0 | 0 | 0 | 0 |

The company conducts research and development of in vitro diagnostic products. It is expected that earnings will cover expenses incurred.

Net expenses for research and development in 2021 of NOK 35.344.043,-, including government grant for 2020 of NOK 1.734.395.

Estimated government grant for 2021 of NOK 2.956.355 is not included in 2021 accounts.



Figures given in thousands

Note 7 - Goodwill

| | Nycomed | Shanghai Upper Biotech | Total |
|--|----------|---------------------------|----------|
| Cost price 01.01.2021 | 37 229 | 1 819 | 39 048 |
| Additions | 0 | 0 | 0 |
| Cost price 31.12.2021 | 37 229 | 1 819 | 39 048 |
| Acc. depreciation and write-downs 01.01.2021 | 37 229 | 1 819 | 39 048 |
| Carrying amount 31.12.2021 | 0 | 0 | 0 |
| Ordinary depreciation for the year | 0 | 0 | 0 |

Note 8 - Other financial revenue

| | 2021 | 2020 |
|------------------------|---------------|---------------|
| Foreign exchange gains | 42 124 | 85 269 |
| TOTAL | 42 124 | 85 269 |

Note 9 - Other financial cost

| | 2021 | 2020 |
|-----------------------|---------------|---------------|
| Foreign exchange loss | 40 792 | 81 314 |
| Sum | 40 792 | 81 314 |

Note 10 - Extraordinary income

In 2021 the company sold Intellectual Property to an Abbott-affiliate for NOK 3.720.864.560, and has also reported gain on sale of shares in subsidiaries of NOK 195.485.250.



Figures given in thousands

Note 11 - Tax

| Allocation of tax expense | 2021 | 2020 |
|----------------------------------|----------------|---------------|
| Tax payable | 466 934 | 41 551 |
| Change in deferred tax | 420 193 | -4 294 |
| Total tax expense | 887 127 | 37 258 |

| Calculation of the tax base for the year | 2021 | 2020 |
|---|------------------|----------------|
| Profit before tax | 4 229 617 | 169 468 |
| Permanent differences | -197 220 | -115 |
| Changes in temporary differences | -1 909 970 | 19 516 |
| The year's tax base | 2 122 427 | 188 870 |

| Temporary differences: | 2021 | 2020 |
|-------------------------------|------------------|-----------------|
| Account receivables | -2 233 | -767 |
| Inventory | -12 514 | -25 377 |
| Tangible assets | -22 594 | -55 908 |
| Provision | -18 465 | -23 277 |
| Pension | 0 | -15 |
| Profit and loss account | 1 860 432 | 0 |
| total | 1 804 626 | -105 344 |

total 1 804 626 -105 344

Deferred tax (assets) 22 % 397 018 -23 176

| Explanation of why the tax charge for the year is not to 22 % of net result before tax: | 2021 | 2020 |
|--|----------------|---------------|
| 22 % tax on the result before tax | 930 516 | 37 283 |
| Permanent differences 22 % | -43 388 | -25 |
| Calculated tax charge | 887 127 | 37 258 |

Effective tax rate 21,0 % 22,0 %



Figures given in thousands

Note 12 - Equity

| | Share capital | Share premium | Retained earnings | Total |
|--------------------|---------------|---------------|-------------------|------------|
| Equity 01.01.2021 | 1 000 | 41 095 | 914 500 | 956 595 |
| Profit of the year | | | 3 342 489 | 3 342 489 |
| Dividend | | | -3 850 000 | -3 850 000 |
| Equity 31.12.2021 | 1 000 | 41 095 | 406 990 | 449 085 |



Figures given in thousands

Note 13 - Intercompany loan

| | 2021 | 2020 |
|------------------------------------|------------------|----------------|
| Receivables | | |
| Intercompany accounts | 146 818 | 105 407 |
| Intercompany long term-receivables | 4 063 549 | 842 504 |
| TOTAL | 4 210 367 | 947 911 |
| Liabilities | | |
| Intercompany accounts payable | 33 669 | 29 349 |
| TOTAL | 0 | 0 |

Receivables maturing later than one year

| | 2021 | 2020 |
|------------------------------------|-------------|-------------|
| Intercompany long-term receivables | 4 063 549 | 842 504 |

Debt maturing later than 5 years

| | 2021 | 2020 |
|----------------|-------------|-------------|
| Long-term debt | 0 | 0 |



Figures given in thousands

Note 14 - Inventory

| Inventory | 2021 | 2020 |
|------------------------|----------------|----------------|
| Raw materials | 60 756 | 51 821 |
| Semi finished goods | 38 279 | 57 837 |
| Finished goods | 13 119 | 667 |
| TOTAL INVENTORY | 112 154 | 110 326 |

Inventory value is per 31.12.2021 valued at acquisition cost or manufacturing cost.

Note 15 - Bank deposits

Of cash and cash equivalents, the following are:

| | 2021 | 2020 |
|-------------------------|-------------|-------------|
| Restricted bank deposit | 7 166 | 8 456 |

The company is a part of Abbott Laboratories group cash pool. This means that all participating companies' withdrawals and deposits are netted against each other and the credit granted is calculated against the netted balance. All participants are jointly responsible for the groups liabilities to the bank, this includes credit limit, interests and fees. Ansvaret is limited according to The Norwegian Companies Act §1-4 and §8-7.

Per 31.12.2021 Abbott Diagnostics Technologies AS has NOK 52 916 287 in the Group cash pool. This is included in the Receivables intercompany amount.



Figures given in thousands

Note 16 - Share capital and shareholder information

| Development in the company's own shares | Number | Face value per share | Booked value |
|---|--------|----------------------|--------------|
| Ordinary shares pr. 31.12.2021 | 1 000 | 1 000 | 1 000 000 |

Overview of the shareholders per 31.12.2021

| | Number |
|----------------|--------|
| Axis-Shield AS | 1 000 |

Abbott Laboratories Inc prepares consolidated financial statements where Abbott Diagnostics Technologies AS is included.

Consolidated financial statements can be provided by Abbott Laboratories with the address:

Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-3500
USA

Note 17 - Financial Market Risk

Currency risk

Currency fluctuations represent both a direct and indirect financial risk for the company. The corporation has an active currency hedge policy, and makes ongoing assessment of exposure.



Figures given in thousands

Note 18 - Transactions with related parties

The balance sheet includes the following amounts as a result of transactions with associated companies:

| | 2021 | 2020 |
|------------------------------|-----------|---------|
| Sale of goods to: | | |
| Intercompany | 1 112 404 | 851 365 |
| Sales of services to: | | |
| Intercompany | 864 | 864 |
| Purchase of goods: | | |
| Intercompany | 278 | 2,5 |
| Purchase of services: | | |
| Intercompany | 89 507 | 74 010 |
| Financial items | | |
| Interest income: | | |
| Intercompany | 3 860 | 2 212 |
| Interest expense: | | |
| Intercompany | 129 | 90 |
| Extraordinary income: | | |
| Intercompany | 3 720 865 | 0 |

Note 19 - The impact of covid-19

The year 2021 was essentially characterized by COVID 19. The company has implemented appropriate measures for its employees, who have continued to work and have not had to interrupt the company activities. The company remained profitable in 2021 even with COVID 19 still being evident. The company will monitor all activities of the pandemic and introduce all measures necessary to continue to deliver a profitable performance in 2022.

Note 20 - Going concern/events after the balance sheet date

There are no significant events after the balance sheet date.